About Blaze Bioscience
Blaze Bioscience is a company based in Seattle (United States) founded in 2010. It operates as a HealthTech. Blaze Bioscience has raised $123.7 million across 12 funding rounds. The company has 27 employees. Blaze Bioscience offers products and services including Tumor Paint, CANVAS Imaging System, and Tozuleristide. Blaze Bioscience operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Seattle, United States
- Employees 27
- SectorsHealthcare
- Phone•••• ••••
- Website blazebioscience.com
- Social LinkedIn X
- Legal Name Blaze Bioscience, Inc.
- Total Equity Funding$123.7M (USD)
in 12 rounds
- Latest Funding Round$8.06M (USD), Series D
Feb 2024
- Employee Count27
Products & Services of Blaze Bioscience
Blaze Bioscience offers a comprehensive portfolio of products and services, including Tumor Paint, CANVAS Imaging System, and Tozuleristide.
Technology is used for cancer detection and removal.
System is designed to enhance cancer treatment imaging.
Drug is developed for cancer surgery imaging applications.
Funding Insights of Blaze Bioscience
Blaze Bioscience has successfully raised a total of $123.7M across 12 strategic funding rounds. The most recent funding activity was a Series D round of $8.06 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $123.7M
- Total Rounds 12
- Last Round Series D — $8.06M
- First Round $725,000
(Oct 2011)
Latest 10 of 12 funding rounds of Blaze Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $8.06M | Series D | – | – | – |
| Oct 2022 | $25M | Series D | – | – | – |
| Oct 2021 | $15M | Series D | – | – | – |
| Oct 2020 | $10M | Series C | – | – | – |
| Apr 2020 | $20.23M | Series C | – | – | – |
| May 2018 | $3M | Series C | – | – | – |
| Oct 2017 | $16.11M | Series C | – | – | – |
| Jan 2016 | $991,000 | Series B | – | – | – |
| Jun 2015 | $9.71M | Series B | – | – | – |
| Feb 2013 | $8.5M | Series A | – | – | – |
People of Blaze Bioscience
10 people are tracked at Blaze Bioscience (3 in leadership, 4 in board & advisors, 3 in team); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
Phillip Uribe | Director Translational Sciences | Leadership |
Christina Walker | Executive Director, CMC | Leadership |
Sean Dixey, SPHR | Director of Human Resources | Leadership |
Jan Öhrström | Chairman | Board & advisors |
Richard G. Ellenbogen | Advisor | Board & advisors |
James Olson | Scientific Founder & Advisor | Board & advisors |
Adam Mamelak | Advisor | Board & advisors |
Mila Lobanova | EVP, Finance & Operations | Team |
Kristi Harrington | SVP of Clinical | Team |
Karen Steffen | Contract Manufacturing Project Management | Team |
Complete people profiles for Blaze Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Blaze Bioscience
3 dated milestones of Blaze Bioscience across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Blaze Bioscience is founded.
- Funding First funding round of $725K.
- Funding Latest funding round, Series D, of $8.1M.
Competitors of Blaze Bioscience
Blaze Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Blaze Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Blaze Bioscience
The website of Blaze Bioscience (blazebioscience.com) receives about 4.1K visits a month.
- Monthly visits4.1K
▲ 112% vs previous month
Latest news on Blaze Bioscience
Complete news archive for Blaze Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Blaze Bioscience
10 companies that operate in the same segment as Blaze Bioscience (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Blaze Bioscience
Blaze Bioscience was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Blaze Bioscience is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Blaze Bioscience is a funded company, having raised a total of $123.7M across 12 funding rounds to date. The company's 1st funding round was a Series A of $8.5M, raised on Oct 2011.
Blaze Bioscience has 27 employees.
Blaze Bioscience, Inc. is dedicated to enhancing the lives of cancer patients through innovative biotechnology solutions. The company is engaged in the development of Tumor Paint technology, including the CANVAS imaging system, to improve the detection, removal, and treatment of cancers. Solutions are aimed at making cancer management more sensitive, reliable, and accessible. The focus is placed on applications in cancer surgery, high-risk surveillance, and screening through collaborations and partnerships.
Blaze Bioscience's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Blaze Bioscience offers Tumor Paint, CANVAS Imaging System, and Tozuleristide.
Blaze Bioscience operates through Blaze Bioscience, Inc..